441 related articles for article (PubMed ID: 3877862)
1. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
4. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
[TBL] [Abstract][Full Text] [Related]
5. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
6. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice.
Ecarot B; Glorieux FH; Desbarats M; Travers R; Labelle L
J Bone Miner Res; 1995 Mar; 10(3):424-31. PubMed ID: 7785464
[TBL] [Abstract][Full Text] [Related]
7. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
[TBL] [Abstract][Full Text] [Related]
8. [Parathormone and vitamin d3-metabolites in healthy children and children with chronic renal failure before and after kidney transplantation].
Pistor K; Reinhardt D; Grosse-Hohmann E; Keck E
Monatsschr Kinderheilkd; 1982 Sep; 130(9):714-20. PubMed ID: 6755227
[TBL] [Abstract][Full Text] [Related]
9. Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites: evidence for the requirement of 1,25(OH)2D3 and 24,25(OH)2D3.
Massry SG; Tuma S; Dua S; Goldstein DA
J Lab Clin Med; 1979 Jul; 94(1):152-7. PubMed ID: 469372
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D metabolism in women with femoral neck fracture.
Hordon LD; Peacock M
Bone Miner; 1987 Aug; 2(5):413-26. PubMed ID: 2851340
[TBL] [Abstract][Full Text] [Related]
11. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
Voigts AL; Felsenfeld AJ; Llach F
Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
[TBL] [Abstract][Full Text] [Related]
12. Effects of 1 alpha,25- and 24R,25-dihydroxyvitamin D3 on aluminum-induced rickets in growing uremic rats.
Vukicević S; Krempien B; Stavljenić A
J Bone Miner Res; 1987 Dec; 2(6):533-45. PubMed ID: 3502683
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D metabolites and bone mineralization in man.
Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
[TBL] [Abstract][Full Text] [Related]
14. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results.
Coen G; Mazzaferro S; Bonucci E; Ballanti P; Massimetti C; Donato G; Landi A; Smacchi A; Della Rocca C; Cinotti GA
Miner Electrolyte Metab; 1986; 12(5-6):375-82. PubMed ID: 3492662
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of secondary hyperparathyroidism with vitamin D metabolites].
Stojimirović B; Pejanović S; Djukanović Lj
Srp Arh Celok Lek; 1994; 122(7-8):197-9. PubMed ID: 17974384
[TBL] [Abstract][Full Text] [Related]
16. Plasma 1,25(OH)2D3 and iPTH in transplanted adults with persisting hypophosphataemia.
Ulmann A; Chkoff N; Garabedian M; Lacour B; Descamps JM; Kreis H; Crosnier J; Funck-Brentano JL
Proc Eur Dial Transplant Assoc; 1980; 17():467-72. PubMed ID: 7017692
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
[TBL] [Abstract][Full Text] [Related]
18. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure.
Lu KC; Lin SH; Yu FC; Chyr SH; Shieh SD
Miner Electrolyte Metab; 1995; 21(6):398-402. PubMed ID: 8592483
[TBL] [Abstract][Full Text] [Related]
19. [Effect of 24,25-dioxycholecalciferol on calcium-phosphorus metabolism and bone tissue in rats with experimental renal failure].
Alekseeva IA
Vopr Pitan; 1984; (3):55-8. PubMed ID: 6332422
[TBL] [Abstract][Full Text] [Related]
20. Treatment with vitamin 24,25 (OH)2D3 does not change serum levels of 1,25 (OH)2D or urinary calcium excretion rate in man.
Thomsen K; Riis BJ; Hummer L; Christiansen C
Acta Vitaminol Enzymol; 1985; 7(3-4):167-71. PubMed ID: 3879105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
